Home Therapeutic Areas Respiratory

Therapeutic Areas

Respiratory

Inhalation and nasal therapies for the regular treatment and prevention of asthma, COPD and allergic rhinitis.
Clinician at work
Our Portfolio

5 products in this therapeutic area

Product information is intended for healthcare professionals. Please refer to the approved prescribing information for full details of indications, dosage and safety.

Flohale

Flohale® (Fluticasone Propionate) 125 mcg & 250 mcg pressurized aerosol for inhalation is indicated for the regular treatment and prevention of asthma attacks.

Nosco

Nosco® (Mometasone Furoate) 50 mcg nasal spray is indicated for the treatment of seasonal and perennial allergic rhinitis, and nasal polyps in adults.

Seroflo ciphaler

Seroflo Ciphaler® (Salmeterol Xinafoate/Fluticasone Propionate) 50 mcg/250 mcg & 50 mcg/500 mcg inhalation powder is indicated for the regular treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).

Seroflo inhaler

Seroflo Inhaler® (Salmeterol Xinafoate/Fluticasone Propionate) 25 mcg/125 mcg & 25 mcg/250 mcg aerosol for inhalation is indicated for the regular treatment of asthma.

Pulmirema

PULMIREMA® (Budesonide) 0.25 mg, 0.5 mg & 1 mg nebuliser suspension is indicated for the control and prevention of asthma symptoms.

Manufactured to international standards

Every product in this portfolio is made under cGMP, in facilities aligned to SFDA, PIC/S, ISO and WHO expectations.
Enquiries

Looking for product information?

Our medical and regulatory teams can support healthcare professionals with product enquiries and prescribing information.